Topics

We combine analyses of lipids, thrombosis and metabolism in acute myocardial infarction, heart failure and structural heart disease. The mission of our group is to gain a detailed understanding of the interplay between metabolism, lipids and coagulation in cardiovascular disease in order to identify targets for primary and secondary prevention. Our aim is to translate these targets into clinical medicine.

Collaborators

• Univ.-Prof. Dr. med. B. Levkau (Heinrich-Heine-University Düsseldorf)
• Univ.-Prof. Dr. med. R. Ahrends (University Wien)
• Prof. Dr. rer. nat. J. Mitchell (Imperial College London)
• PD Dr. med. Tobias Petzold (Charité Berlin)

Selected publications

• Polzin A, Benkhoff M, Thienel M, Barcik M, Mourikis P, Shchurovska K, Helten C, Ehreiser V, Zhe Z, von Wulffen F, Theiss A, Peri S, Cremer S, Ahlbrecht S, Zako S, Wildeis L, Al-Kassis G, Metzen D, Utz A, Hu H, Vornholz L, Pavic G, Lüsebrink E, Strecker J, Tiedt S, Cramer M, Gliem M, Ruck T, Meuth SG, Zeus T, Mayr C, Schiller HB, Simon L, Massberg S, Kelm M, Petzold T. Long-term FXa inhibition attenuates thromboinflammation after acute myocardial infarction and stroke by platelet proteome alteration. J. Thromb. Haemost. 2024 Nov.
• Benkhoff M, Barcik M, Mourikis P, Dahlmanns J, Kahmann P, Wollnitzke P, Hering M, Huckenbeck T, Hoppe J, Semleit N, Deister-Jonas J, Zako S, Seel J, Coman C, Barth M, Cramer M, Helten C, Wildeis L, Hu H, Al-Kassis G, Metzen D, Hesse J, Weber J, Dannenberg L, Akhyari P, Lichtenberg A, Quast C, Gerdes N, Zeus T, Borst O, Kelm M, Petzold T, Ahrends R, Levkau B, Polzin A. Targeting Sphingosine-1-Phosphate Signaling to Prevent the Progression of Aortic Valve Disease. Circulation. 2024 Okt.
• Møller JE, Engstrøm T, Jensen LO, Eiskjær H, Mangner N, Polzin A, Schulze PC, Skurk C, Nordbeck P, Clemmensen P, Panoulas V, Zimmer S, Schäfer A Werner N, Frydland M, Holmvang L, Kjærgaard J, Sørensen R, Lønborg J, Lindholm MG, Udesen NLJ, Junker A, Schmidt H, Terkelsen CJ, Christensen S, Christiansen EH, Linke A, Woitek FJ, Westenfeld R, Möbius-Winkler S, Wachtell K, Ravn HB, Lassen JF, Boesgaard S, Gerke O, Hassager C; DanGer Shock Investigators. Microaxial Flow Pump or Standard Care in Infarct-Related Cardiogenic Shock. N Engl J Med. 2024 Apr.
• Polzin A, Dannenberg L, Benkhoff M, Barcik M, Helten C, Mourikis P, Ahlbrecht S, Wildeis L, Ziese J, Zikeli D, Metzen D, Hu H, Baensch L, Schröder NH, Keul P, Weske S, Wollnitzke P, Duse D, Saffak S, Cramer M, Bönner F, Müller T, Gräler MH, Zeus T, Kelm M, Levkau B. Revealing concealed cardioprotection by platelet Mfsd2b-released S1P in human and murine myocardial infarction. Nat. Commun. 2023 Apr.
• Thienel M, Müller-Reif JB, Zhang Z, Ehreiser V, Huth J, Shchurovska K, Kilani B, Schweizer L, Geyer PE, Zwiebel M, Novotny J, Lüsebrink E, Little G, Orban M, Nicolai L, El Nemr S, Titova A, Spannagl M, Kindberg J, Evans AL, Mach O, Vogel M, Tiedt S, Ormanns S, Kessler B, Dueck A, Friebe A, Jørgensen PG, Majzoub-Altweck M, Blutke A, Polzin A, Stark K, Kääb S, Maier D, Gibbins JM, Limper U, Frobert O, Mann M, Massberg S, Petzold T. Immobility-associated thromboprotection is conserved across mammalian species from bear to human. Science. 2023 Apr.
• Petzold T, Zhang Z, Ballesteros I, Saleh I, Polzin A, Thienel M, Liu L, Ul Ain Q, Ehreiser V, Weber C, Kilani B, Mertsch P, Götschke J, Cremer S, Fu W, Lorenz M, Ishikawa-Ankerhold H, Raatz E, El-Nemr S, Görlach A, Marhuenda E, Stark K, Pircher J, Stegner D, Gieger C, Schmidt-Supprian M, Gaertner F, Almendros I, Kelm M, Schulz C, Hidalgo A, Massberg S. Neutrophil "plucking" on megakaryocytes drives platelet production and boosts cardiovascular disease. Immunity. 2022 Dec.
• Polzin A, Dannenberg L, Benkhoff M, Barcik M, Keul P, Helten C, Zeus T, Kelm M, Levkau B. S1P Lyase Inhibition Starting After Ischemia/Reperfusion Improves Postischemic Cardiac Remodeling. JACC Basic Transl. Sci. 2022 May.
• Piayda K, Phinicarides R, Afzal S, Veulemans V, Jung C, Bönner F, Kelm M, Hellhammer K, Polzin A, Zeus T. Dynamic Coronary Roadmap in Percutaneous Coronary Intervention: Results from an Open-Label, Randomized Trial. JACC Cardiovasc. Interv. 2021 Nov.
• Petzold T, Thienel M, Dannenberg L, Mourikis P, Helten C, Ayhan A, M'Pembele R, Achilles A, Trojovky K, Konsek D, Zhang Z, Regenauer R, Pircher J, Ehrlich A, Lüsebrink E, Nicolai L, Stocker TJ, Brandl R, Röschenthaler F, Strecker J, Saleh I, Spannagl M, Mayr CH, Schiller HB, Jung C, Gerdes N, Hoffmann T, Levkau B, Hohlfeld T, Zeus T, Schulz C, Kelm M, Polzin A. Rivaroxaban Reduces Arterial Thrombosis by Inhibition of FXa-Driven Platelet Activation via Protease Activated Receptor-1. Circ. Res. 2020 Feb.
• Keul P, Polzin A, Kaiser K, Gräler M, Dannenberg L, Daum G, Heusch G, Levkau B. Potent anti-inflammatory properties of HDL in vascular smooth muscle cells mediated by HDL-S1P and their impairment in coronary artery disease due to lower HDL-S1P: a new aspect of HDL dysfunction and its therapy. FASEB J. 2018 Aug.
• Polzin A, Zeus T, Schror K, Kelm M, Hohlfeld T. Dipyrone (metamizole) can nullify the antiplatelet effect of aspirin in patients with coronary artery disease. JACC. 2013 Aug.